DOPAMINE HYDROCHLORIDE (dopamine hydrochloride) by Pfizer is 3,4 dihydroxyphenylalanine (dopa). Approved for hemodynamic status in patients in shock. First approved in 1981.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
Dopamine hydrochloride is an injectable catecholamine used to manage hemodynamic instability in shock patients. It works as a natural neurotransmitter precursor that activates dopamine D1/D2, beta-1, and alpha-1 receptors in a dose-dependent manner, increasing cardiac contractility and blood pressure.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100); teams likely focused on defending legacy market share rather than growth initiatives.
3,4 dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal tract, and in a few peripheral sympathetic nerves. Dopamine elicits its pharmacological…
Working on dopamine HCl offers limited career growth due to its mature, commoditized status and approaching LOE. Roles focus on defending hospital relationships, managing payer contracts, and cost optimization rather than product innovation or market expansion.
Worked on DOPAMINE HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo